New research backs CDY’s MK plan for osteoporosis
Published 09-AUG-2016 15:40 P.M.
2 minute read
Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.
In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.
The below articles were written under our previous business model. We have kept these articles online here for your reference.
Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.
Click Here to View Latest Articles
Cellmid (ASX:CDY) has received a boost with more academic research backing its midkine antibody’s potential in improving bone quality and fracture healing in osteoporosis models.
It told its shareholders today that a team of German researchers had found that MK antibodies could help in the healing of fractured bones in a validated model of osteoporosis in rodents – with the research published in journal PLoS One.
A previous study by the same researchers found that CDY’s MK antibody accelerated bone fracture healing in otherwise normal rodents.
Lead researcher Dr Astrid Liedert found that the application of CDY’s MK antibody in the rodent osteoporosis model improved the rate of fracture healing in both normal and osteoporotic animals.
The studies are still at a very early stage and any antibodies could still be a fair way off commercialisation – investors should consult a professional financial advisor before investing.
Dr Liedert also made the observation that the loss of bone mineral density and volume in otherwise intact but osteoporotic bones “some distance away” from the fracture site was reversed following the MK application.
The findings further cements CDY’s MK antibodies, which were found to accelerate bone healing in osteoporotic settings.
The upshot is that the MK antibodies could potentially be used by elderly patients with osteoporosis to help bone healing.
Osteoporotic patients have reduced bone regeneration capabilities, making bone healing especially difficult – and 30% of post-menopausal women suffer osteoporotic fractures after the age of 50.
Apart from the quality of life issues associated with fractures taking longer to heal, fractures can often cause severe and potentially life threatening complications for elderly patients.
The MK antibodies are under CDY’s subsidiary Lyramid, and CDY has filed patent applications covering the use of MK antibodies for fracture healing and restoring bone loss due to osteoporosis.
MK has been shown to be an important early marker for diagnosing various diseases and is only evident in a disease context. Unlike many other forms of treatment, targeting MK is not expected to harm normal health tissue.
While there are still hurdles to surmount before CDY and Lyramid can proceed to human trials, the further academic validation would be a boon to the company.
General Information Only
S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.
Conflicts of Interest Notice
S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.
Publication Notice and Disclaimer
The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.
Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.
This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.